Adipose tissue-derived stem cells (ADSCs) have been considered a promising treatment for diabetic wound repair. However, the effectiveness of autologous ADSC-derived therapy for diabetic patients needs to be improved. The aim of this study was to investigate the effect
More
Adipose tissue-derived stem cells (ADSCs) have been considered a promising treatment for diabetic wound repair. However, the effectiveness of autologous ADSC-derived therapy for diabetic patients needs to be improved. The aim of this study was to investigate the effect of pretreatment with deferoxamine on the expression of the angiogenic genes in diabetic ADSCs preconditioned with deferoxamine. In this experimental study, abdominal adipose tissue was taken from three patients with type 2 diabetes and three healthy individuals, and stem cells derived from adipose tissue were extracted by the enzymatic method. Diabetic ADSCs were treated with 75, 150, and 300 μM deferoxamine concentrations for 24 and 48 hours. Then, the cell survival rate was evaluated using the WST1 test and the expression level of VEGF, ANGP1, and TFGβ1 genes in normal, diabetic, and diabetic ADSCs treated with deferoxamine using the Real-time PCR technique. The data were analyzed using Prism statistical software. Our results showed that the expression levels of VEGF, ANGP1 and TGFβ1 genes in diabetic samples were significantly decreased compared to the normal group (P<0.05). However, the expression level of all three genes after treating the cells with concentrations of 150 and 300 μM deferoxamine for 24 hours was significantly increased compared to the untreated diabetic group (P<0.05). Our results showed that deferoxamine significantly increases the expression of VEGF, ANGP1, and TGFβ1 in diabetic ADSCs and increases their angiogenic capacity.
Manuscript profile
